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Abstract
Background: The Epstein-Barr virus is widespread in all human populations and is strongly
associated with human disease, ranging from infectious mononucleosis to cancer. In infected cells
the virus can adopt several different latency programs, affecting the cells' behaviour. Experimental
results indicate that a specific genetic switch between viral latency programs, reprograms human
B-cells between proliferative and resting states. Each of these two latency programs makes use of
a different viral promoter, Cp and Qp, respectively. The hypothesis tested in this study is that this
genetic switch is controlled by both human and viral transcription factors; Oct-2 and EBNA-1. We
build a physico-chemical model to investigate quantitatively the dynamical properties of the
promoter regulation and experimentally examine protein level variations between the two latency
programs.
Results: Our experimental results display significant differences in EBNA-1 and Oct-2 levels
between resting and proliferating programs. With the model we identify two stable latency
programs, corresponding to a resting and proliferating cell. The two programs differ in robustness
and transcriptional activity. The proliferating state is markedly more stable, with a very high
transcriptional activity from its viral promoter. We predict the promoter activities to be mutually
exclusive in the two different programs, and our relative promoter activities correlate well with
experimental data. Transitions between programs can be induced, by affecting the protein levels of
our transcription factors. Simulated time scales are in line with experimental results.
Conclusion: We show that fundamental properties of the Epstein-Barr virus involvement in latent
infection, with implications for tumor biology, can be modelled and understood mathematically.
We conclude that EBNA-1 and Oct-2 regulation of Cp and Qp is sufficient to establish mutually
exclusive expression patterns. Moreover, the modelled genetic control predict both mono- and
bistable behavior and a considerable difference in transition dynamics, based on program stability
and promoter activities. Both these phenomena we hope can be further investigated
experimentally, to increase the understanding of this important switch. Our results also stress the
importance of the little known regulation of human transcription factor Oct-2.
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Background
Epstein-Barr virus (EBV) primary infection usually occurs
early in childhood until teens, and then persists through-
out life as latent infection in a fraction of B-lymphocytes
in more than 90% of adults. One adverse consequence of
the infection is an increased tumour risk [1]. There are
some 170.000 new EBV-positive tumours occurring annu-
ally in the global human population, of which half derive
from the hematopoietic compartment and half from epi-
thelial precursors. The tumour risk is thought to be intrin-
sic to the viral strategy for survival and spread. Indeed, the
ability of the virus to transiently induce proliferation of
latently infected B-lymphocytes results in an increased
pool of infected cells. This induction of proliferation
depends on the switch between viral latent programs in
the cell, which can bring the cell from resting state, into
active cell cycle and back to resting. If this switch gets out
of balance, more proliferation leads to a higher load of
virus-infected cells and hypothetically increases the risk
for lymphoma development. The mechanisms controlling
induction of proliferation are not understood. The most
upstream event that can be identified until now is the
switch between two viral promoters, the Q promoter (Qp)
and the C promoter (Cp), which in turn determines
expression of key regulatory viral proteins. Here we
present an in silico study of this viral switch, involving one
viral and one human protein. The aim is to investigate
whether this simplified model can explain the availabel
experimental data, as well as opening the field of EBV
research to modeling.
The EBV genome is a 172 kbp long double-stranded DNA
which during latent infections is maintained in the
nucleus of the host cells as an extra-chromosomal circular
episome. Twelve viral genes can be expressed in different
combinations during latent viral infection, while the
remaining 70 major open reading frames are expressed
during the replicative, lytic cycle [2]. During latency EBV
genes are expressed in four programs, denoted latency 0,
I, II and III. In latency III all 12 latency genes are
expressed, including six nuclear proteins, EBNA-1-6, three
membrane proteins (LMP-1, LMP-2A and LMP-2B), BART
and two small non-translated RNAs (EBER 1 & 2). In
latency II, the viral genes for EBNA-1, the three membrane
proteins and the EBERs are expressed while in latency
state 0/I, only LMP2a and variably EBNA-1 are expressed
[2,3]. B-lymphocytes in latency III are proliferating, driven
by the viral gene products, while the remaining latency
forms are in non-proliferating, resting cells. An essential
viral protein is EBNA-1; responsible for viral replication,
episome partitioning as well as functioning as regulator of
gene transcription [4]. EBNA-1 is therefore expressed in all
latent programs, but the mRNA transcripts results from
different promoters; Cp in latency III and Qp in latency I
[5-8]. It is believed that the two promoters are mutually
exclusive due to different EBNA-1 levels between the
latency programs [6,9].
The Cp transcripts produce all six EBNA-proteins from
bicistronic mRNAs modulated by alternative splicing
[10]. Its activity is directed by several regulatory sequences
of which the enhancer 'family of repeats' (FR) region is the
major regulatory site. FR consists of multiple EBNA-1 and
octamer binding sites, in an alternating pattern [11], and
EBNA-1 binding to FR is required for transcriptional acti-
vation [6,12,13]. The enhancement of Cp by EBNA-1
bound at FR follows a complicated pattern, where at least
eight of the 20 present sites need to be occupied by EBNA-
1 for full transcriptional activation [14,15]. The human
transcription factors Oct-2 and Oct-1 in association with
Bob.1, have been shown to activate Cp, while Oct-2 in
association with members of the Groucho (Grg/TLE) –
family of proteins acts as an inhibitor of Cp [11,16]. Oct-
1 is however not the prime candidate for operating the
switch since it is not B-cell specific, like Oct-2, and more-
over there is little or no difference in Oct-1 levels between
latency I and III cells (Almqvist J et al.: Repression of
Epstein-Barr virus enhancer Family of Repeats mediated
transcription by Oct and Grg/TLE transcriptional regula-
tors, suggest an involvement in switching between latency
states, submitted). Oct-2 levels, on the contrary, differ
between latency I and III (as shown in this study), indicat-
ing that Oct-2 is the dynamic inhibitory protein, even
though it requires to bind FR in complex with Grg/TLE to
be inhibitory [16].
Between FR and the initiation site there are other regula-
tory sequences such as an EBNA-2-dependent enhancer
[17,18], GRE, a glucocorticoid-responsive enhancer [19],
and sites for Egr, Sp1 and NF-Y transcription factors [20].
Deletion analysis however indicated that the GRE is not
necessary for transcription initiation, and the EBNA-2
dependent enhancer is not sufficient to activate Cp [21].
Moreover, Sp1 and NF-Y are two ubiquitously expressed
proteins known to interact with each other [22], and NF-
Y is suggested to play a role in basal transcriptional regu-
lation [22,23], with binding sites in 30% of all eukaryotic
promoters [24]. Taken together, these experimental data
indicate that EBNA-1 is the major activator of the C pro-
moter.
In contrast to Cp, Qp governs expression of a monocis-
tronic EBNA-1 transcript and is thought to be a house-
keeping promoter of latency I since it lacks TATA sequence
upstream of the initiation site, like many cellular house-
keeping genes [25]. Experimental studies of Qp regulation
have revealed three types of transcription factors binding
in the promoter region; EBNA-1, E2F and IRF. IRF factors
have been shown to constituitively activate Qp, with theBMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
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role of directing general transcription factors in the
absence of a TATA box [9,26]. The information concern-
ing E2F regulation is less consistent, since E2F has been
shown to both activate and inhibit Qp [27,28]. There is
however no doubt that Qp is negatively auto-regulated
through binding of EBNA-1 to the two binding sites
downstream of the initiation site [6,8,27,29], and that
one occupied site is enough to block Qp activity [6].
Transcriptional control of genes is not trivial to model,
especially not for eukaryotic systems with complex regula-
tory machinery. However, a main dynamic regulatory
mechanism is the binding of inhibitory or stimulatory
transcription factors to operator sites on the DNA. Assum-
ing that the rates for binding and unbinding of transcrip-
tion factors are much faster than the rates for open
complex formation and elongation, these bindings are in
homeostatic equilibrium with the instantaneous tran-
scription factor concentrations [30,31]. This is the basis
for modelling gene transcription probabilities with ther-
modynamic models, as has successfully been used to
describe genetic switches in coliphage systems [30-33].
In this paper we construct a physico-chemical model of
the switch between EBV latency I and latency III. The
model is based on the hypothesis that promoter control
by EBNA-1 and Oct-2 is sufficient to switch between Cp
and Qp usage in the two latency programs. Even though
this is a simplification, the experimental data summarized
above point to EBNA-1 as the major regulatory factor in
controlling both promoter activities, and to Oct-2 in com-
plex with Grg/TLE as a candidate for inhibitory control of
Cp. In our model, Cp is thus switched on by EBNA-1 and
switched off by Oct-2+Grg/TLE, while Qp is switched off
by EBNA-1 and is otherwise on. Figure 1 gives a schematic
overview of the model.
While this system belongs to the same general class of sys-
tems studied previously, a distinguishing feature of our
system is the relatively large number of number of bind-
ing sites, and the complicated observed dependence of
activation on the number of EBNA-1 bound. This theoret-
ical approach to understand EBV-induced cell prolifera-
tion is to be seen as an extension of experimental studies
and a first step towards a system level description of EBV
infections.
Results
The two states latency I and latency III can be studied in
human EBV-positive B-cell lines either derived from
tumors or transformed in vitro by the virus. Cells in latency
I without exception show lower levels of EBNA-1 and
higher levels of Oct-2 compared cells in latency III ([11];
Almqvist J et al.: Repression of Epstein-Barr virus enhancer
Family of Repeats mediated transcription by Oct and Grg/
TLE transcriptional regulators, suggest an involvement in
switching between latency programs, submitted). An
example of a qualitative comparison of EBNA-1 and Oct-
2, as detected in Western blot in the two types of cells, is
shown in Figure 2a. We have estimated the quantitative
differences between the intensities of the bands in Figure
2a, and in several different pairs of latency I and III cells
(data not shown), using the ImageJ densitometry program
(NIH). The EBNA-1 signal was between 2.8–4.7 times
higher in latency III compared to latency I cells, while Oct-
2 was 2.1–3.3 times higher in latency I cells compared to
latency III. In vivo binding of both EBNA-1 and Oct-2 to
FR in these two cell types can be demonstrated by a CHIP-
assay (Figure 2b).
Latency states in the model
Our model displays regions of mono-stability, with either
latency I or III as the only stable state, and a region of bi-
stability. For low Oct-2+Grg/TLE levels, only latency III is
stable, while, for higher levels, there is a bistable region.
This eventually gives way to the monostable latency I, at
even higher Oct-2+Grg/TLE levels. The net effects of pro-
duction from the two promoters together with dilution
and decay can conveniently be visualized by a production
potential. The negative derivative of this potential, with
respect to the number of EBNA-1, correspond to the net
production rate of EBNA-1. Figure 3 displays this produc-
tion potential for three different levels of Oct-2+Grg/TLE.
At intermediate Oct-2+Grg/TLE levels, the system is bista-
ble, i.e. the production potential has two local minima
(dashed line). Increasing the Oct-2+Grg/TLE level eventu-
ally eliminates latency III (dotted line), while decreasing
Oct-2+Grg/TLE level eliminates latency I (solid line).
In our model, the level of EBNA-1 in the two stable states
is dependent on the Oct-2+Grg/TLE levels, as can be seen
from the positions of the minima in Figure 3. The model
has a latency III level of EBNA-1 around 34,000 proteins
(this value is calibrated to published data, see Methods)
when no Oct-2+Grg/TLE complexes are present. This level
decreases to around 14,000 after which point this latency
state vanishes.
The EBNA-1 level in latency I varies less with Oct-2+Grg/
TLE levels, remaining around 700–900 proteins (all val-
ues given for parameters presented in Table 1).
Promoter activity
Figure 4 shows computed Cp and Qp activity in our
model, as functions of EBNA-1 and Oct-2+Grg/TLE levels,
demonstrating the remarkably different activity levels of
the two promoters. The Cp activity (blue surface) is 60–
100% of maximum for all Oct-2+Grg/TLE and EBNA-1
levels shown. The Qp activity (red surface) is mostly
around 1%, except at very low EBNA-1 levels. Since theBMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
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half-life of EBNA-1 is long (see Methods), we expect Qp to
only be active at a low level in latency I. Our model indeed
shows very low Qp activity in latency I, both in the mono
and bistable regions. It estimates the Qp activity to be
about 1% of its full capacity in latency I, and close to zero
in latency III. Cp on the contrary is active at 40–100% of
maximum transcription rate in latency III, with the lower
activity in the bistable region. In monostable latency I, the
Cp activity is essentially zero and below 1% active for
latency I in the bistable region. The Cp transcription is
strongly dependent on Oct-2+Grg/TLE levels. However, at
the system volumes tested here, Oct-2+Grg/TLE levels do
not greatly affect Qp activity. To summarize, the two pro-
moters are mutually exclusive in the monostable regions,
although their activity levels differ, and also for the
latency III state in the bistable region. In the latency I state
in the bistable region, the Cp and Qp activities are some-
what comparable. Table 2 summarizes the Cp and Qp
transcription activities presented above.
Stability of the latency programs
The system volume was in our study estimated to be 2 *
10-13 l (see Methods), but was increased and decreased
ten-fold in sensitivity tests. For each volume size, the sta-
ble latency I and III levels of EBNA-1 was computed for
different dimerization dissociation constants for EBNA-1;
10-8 M, 10-9 M and 10-10 M, and varying levels of Oct-2.
Stable steady state levels were also computed for a five-
fold lower Oct-2 affinity to FR. The stability of the two
latency states and their robustness to parameter changes
can be quantified by the externally imposed change on
EBNA-1 levels that induces the system to transit from one
state to the other. This measure is of course appropriate
only in the bi-stable region, where both states exist. As
The genetic switch Figure 1
The genetic switch. This illustration describes the regulatory mechanisms of the modeled switch between the C promoter 
(Cp) and the Q promoter (Qp) in Epstein-Barr virus. Transcripts from Cp are spliced into bicistronic mRNAs coding either for 
EBNA-1 (red) or one of the other EBNA proteins (blue), while transcripts from Qp only codes for EBNA-1. EBNA-1 itself acts 
as a negative regulator of Qp, binding downstream of the transcription start, and positively regulates transcription from Cp 
through binding upstream to the Family of Repeats sequence (FR). FR bind also Oct-2 molecules (green), in complex with Grg/
TLE, acting as inhibitory regulators.BMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
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Protein levels and DNA binding Figure 2
Protein levels and DNA binding. a) Western blot showing EBNA-1 and Oct-2 in latency I type cell Rael (I) and latency III 
type cell CBMI Ral-STO (III). Monoclonal antibodies were used to detect the proteins as described in Methods. b) Chromatin 
immunoprecipitation(CHiP)-assay of EBNA-1 and Oct-2 probed by PCR over the left hand of FR. The antibody-protein cross-
linked and precipitated DNA was probed undiluted, diluted 1:10 and 1:100. The sources of the protein-FR complexes were the 
same cell lines as in a). Controls were immunpreciptation leaving out the first specific antibody, a cloned, purfied piece of FR 
(positive control) and PCR with no DNA (negative control) c) Control of non-specific binding of antibodies to DNA. DNA 
from latency III cell lysate was immunopreciptated with anti-Oct2 or anti-EBNA1, with negative and positive controls. Results 
show no significant background binding of the antibody.BMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
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shown in Figure 5, for most parameters latency III is more
stable than latency I, i.e., a larger change in EBNA-1 levels
is needed to induce a transition from latency III to latency
I than in the opposite direction. [see Additional file 1]
As the left plot in Figure 5 demonstrates, the model is cer-
tainly sensitive to changes in affinity of Oct-2 complex to
FR. With a fivefold increase in affinity of Oct-2 the posi-
tion of the bistable region is shifted towards five times
higher Oct-2 levels, but the relative properties of the
latency states do not change significantly. The right plot in
Figure 5 illustrates the sensitivity of the model to changes
in volume and dimerization constant for EBNA-1. The
impact of changes in the dimerization constant depends
on the system volume, where the larger volume is less
robust. Comparing the red and blue lines in Figure 5, the
effect of increasing the dimerization 10-fold results in a
shift of the bistable region towards higher Oct-2 levels.
This shift is substantially larger for the same dimerization
parameter increase in the larger volume (black and green
lines). The model's response to changes in the volume
parameter is primarily that the bistable region shrinks
with increasing volume, and latency I EBNA-1 levels rise.
Inducing transitions
In Figure 6 we illustrate how our model behaves when
responding to changes in Oct-2+Grg/TLE. Initially, the cell
is in latency I, with 850 EBNA-1 proteins molecules per
cell and 15000 Oct-2+Grg/TLE complexes per cell.
Decreasing the level of the Oct-2+Grg/TLE complex by
30% quickly leads to an increase in Cp activity and hence
an increase in EBNA-1 production. Within four to five
days EBNA-1 levels have reached the levels of stable
latency III. Transitions from latency III to latency I on the
other hand, requires quite high levels of the Oct-2+Grg/
TLE complex for an extended period of time. The affinity
of Oct-2 to FR being about 300 times weaker than the
affinity of EBNA-1, Oct-2+Grg/TLE needs to be in large
excess over EBNA-1 in order to fairly compete for binding
to FR. Given a level of about 34,000 EBNA-1 in latency III,
and the non-linear dependence of Cp activity on EBNA-1
concentration, one needs an Oct-2+Grg/TLE level of
about 100,000 molecules, at least transiently, to lower
EBNA-1 levels sufficiently in 5 days (solid lines in Figure
6). However, the switch can proceed slower with a lower
level of Oct-2 for a longer time (dashed lines in Figure 6).
Table 1: Parameters used in model of the EBV genetic switch
Name Value Reference
KdE*1   nM (0.1 – 10 nM) Assumed model parameter
KdEFR 15 pM [39]
KdOFR* 2.5 nM (2.5 – 12.5 nM)[ 4 1 ]
KdQ 0.21 µM[ 3 9 ]
Etot in lat III 34,000 molecules [43]
τ1/2 48 h [44,45]
cell division time 24 h [46]
Nucleus volume * 2e-13l(2e-14 - 2e-12l)[ 4 8 ]
Each Paramater is presented with a name, also used in the Methods section, and its value and corresponding reference puplication. *The three 
parameters that were altered in robustness tests. The range is given in Parenthesis.
Potential landscape Figure 3
Potential landscape. The potential landscape of the EBV 
kinetic system for three different levels of Oct-2+Grg/TLE. 
The two local minima in the potential landscape corresponds 
to latency I, at low EBNA-1 levels, and latency III, at high 
EBNA-1 levels. Increasing the Oct-2 levels in the system shift 
the latency III minima towards latency I and eventually it dis-
appear completely, leaving the system in a monostable 
latency I state.
0 0.5 1 1.5 2 2.5 3 3.5 4
x 10
4
−2500
−2000
−1500
−1000
−500
0
500
1000
1500
2000
2500
EBNA−1
φ
(
E
B
N
A
−
1
 
 
Oct−2+Grg/TLE=20000
Oct−2+Grg/TLE=35000
Oct−2+Grg/TLE=50000BMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
Page 7 of 13
(page number not for citation purposes)
Both transitions have their lower limits in time, due to
maximum production rate and the slow degradation rate
of EBNA-1.
Discussion
EBV regulates fundamental properties of infected cells,
and survives for long times in the host using different
latency states, where we study the switch between the two
extremes resulting in resting and proliferative states [1,3].
The molecular cell biology of the infection and EBVs asso-
ciation with various cancer types has been extensively
studied. However, in order to fully understand how the
virus survives in, and uses, its host cells we believe it is
necessary to incorporate all information into a full, sys-
tem level description. Our model of the switch between
latency III and I is a first step towards such a model. The
aim, besides opening the EBV research field to modeling,
was to investigate whether EBNA-1 and Oct-2 regulation
of Cp and Qp is sufficient to explain experimental results,
and to identify important questions for further experi-
mental studies.
A key effect in our model is the competitive binding of
EBNA-1 and Oct-2+Grg/TLE to the Cp enhancer FR. Essen-
tial parameter values are hence binding affinities of
EBNA-1 and Oct-2 to cognate sites. These binding affini-
ties together determine the behaviour of the two involved
promoters, and thereby also the switch between latency
programs. Although it is well established that EBV can
activate resting B-cells into proliferating blasts, the ques-
tion how precisely this process is induced is still open. In
our model, in order to keep the cell resting, using only Qp
to produce EBNA-1, a high enough level of Oct-2+Grg/
TLE is necessary in the cell. When Oct-2+Grg/TLE levels
drop, EBNA-1 can access FR and trigger Cp transcription.
Since Cp is positively auto-regulated, working on a high
production rate, EBNA-1 levels then quickly increase once
Cp has been turned on.
We show that our model of the EBV latency switch dis-
plays expected features of the switch. At different Oct-2
concentrations, the switch is either monostable, and then
exhibits states of either latency I or latency III, or is bista-
ble. This behavior is robust to several parameter changes,
although the boundaries and size of the stability domains
vary. That the bistable region extends up to a higher level
of Oct-2 in the system, when lowering Oct-2 affinity to FR,
is to be expected, since a lower affinity requires a higher
Oct-2 level to inhibit Cp transcription. Also, the fact that
the model's sensitivity to changes in EBNA-1 dimerization
is correlated with the system volume, can be explained.
With a smaller system volume, the concentration of
EBNA-1 is higher. With a concentration of EBNA-1 higher
than, or of same order as, the dimerization dissociation
constant, there will be no significant impact in changing
this parameter. Besides correlating with dimerization of
EBNA-1, a noticeable effect of volume increase is the
shrinkage of the bistable region, with respect to Oct-2 lev-
els. This correlates with the larger number of EBNA-1 for
latency I. Latency III amounts of EBNA-1 does not differ
much between different parameter sets since it is deter-
mined from the production rate based on the measured
number of EBNA-1 molecules (see Methods). The latency
I levels however, depends only on the concentration of
EBNA-1 in the cell, due to the negative feedback-loop,
leading this number to vary.
Regarding promoter activities, there is experimental data
for C and Q promoter transcripts in latency I and latency
III cells [6,7]. Shaefer et al. present a Qp/Cp activity ratio
of 5–100 in latency I cells, and 0.05–0.1 for latency III
cells [6]. Zetterberg et al. show that latency I cells have 76–
83% of all EBNA-1 transcripts originating from Qp, while
less than 1% of EBNA-1 transcripts in latency III cells
come from Qp [7]. Our theoretical predictions of activi-
ties of Cp and Qp presented in Table 2 correspond quite
well to these experimental results. The mutual exclusive-
ness discussed in experimental papers agrees with our
results, except for latency I in the bistable region. What is
striking is the dramatic difference in predicted activity for
the two promoters, even when comparing their respective
stable latency states. Since the model is a simplified ver-
sion of the in vivo mechanisms, our activities corresponds
to the scenario without methylation or chromatin remod-
eling. This might explain the relatively low Qp/Cp activity
ratio we see for latency I in the bistable region, since it is
experimentally known that Cp is hypermethylated in
latency I cells [34]. Lieberman's group recently published
data showing that Cp can be regulated by changes in chro-
matin structure exerted by chromatin organizing proteins
CTCF, which has one binding site in the EBV genome
between FR and Cp [35]. This is compatible with our
model as Grg/TLE can act as a chromatin remodelling pro-
tein by de-acetylating histones [36]. We believe it likely
that the transcription factor recruitment and regulation is
upstream of the chromatin regulating events in the switch,
i.e. creates the signal that leads to chromatin remodelling.
There is as yet no experimental system to directly operate
this switch in B cells in vitro. However there are models in
Table 2: Computed C and Q promoter activities for the mono- 
and bi-stable states in both latencies.
Lat III Lat I
bi mono bi mono
Qp - - ≈1% ≈1%
Cp 40 – 90% ≥90% ≤1% -BMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
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EBV positive cell lines, which at least inefficiently mimics
this switch, particularly the latency III to latency I transi-
tion by CD 40 ligand exposure or by RNA interference
[37,38]. Experimental results indicate that proliferating
EBV-transformed immunoblasts can be switched into a
more restricted latency program within 5 days, due to a
decrease in Cp activity [37]. According to our model, for
this transition to occur in 5 days, Oct-2 levels need to be
elevated up to 10-fold. The higher the Oct-2 level already
in latency III, the lower fold increase of Oct-2 is necessary.
The increase is however only required temporarily, since
stable latency I state can persist even for quite low Oct-2
levels. Although a qualitative comparison between our
experimental and theoretical molecular levels is possible,
it is at this stage not enough to determine whether the
switch is carried out between monostable states or in the
bistable region. Further experiments with silencing of Oct-
2 RNA followed by time series measurements on EBNA-1
and Oct-2 levels, should shed light on this matter.
Noise plays an important role in gene regulation and in
models of gene regulation when the levels of regulatory
factors are low, and in primarily dynamic phenomena,
when there is a choice between different pathways. Noise
also decreases stability and robustness of steady states. For
most parameter values in the bistable region, the latency I
state is more easily perturbed than latency III. A conse-
quence is that a switch from latency I to latency III can be
expected to occur in response to smaller external stimuli.
However, since there is no compelling reason for the EBV
switch to operate in the bistable region, the influence of
noise is likely to be small. Furthermore, the protein levels
are relatively high in both latency states, reducing the
impact of stochastic effects.
Although the structure of the FR invites consideration of
cooperative binding of EBNA-1 (and/or Oct-2+Grg/TLE)
to these binding sites, no experimental data is at present
Promoter activity Figure 4
Promoter activity. The probability of transcription from both promoters, Cp (blue) and Qp (red) as function of EBNA-1 and 
Oct-2 proteins in the system. This plot shows the case when Oct-2+Grg/TLE has the maximum binding affinity to FR, KdOFR = 
2.5 nM. The Qp activity is remarkably low for most EBNA-1 levels compared with the Cp activity.
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available. Stress testing the model involving these addi-
tional effects is in progress, and will be reported else-
where. The addition of cooperative binding would not
affect the qualitative functions of the switch, while it
might influence the quantitative measurements, such as
protein levels and the switching times. Another issue in
modelling gene regulatory systems is whether important
entire elements are left out. While this cannot be deter-
mined within a model, the propensity that it is the case
can be adjudged from the model properties. We argue that
our model is consistent with the knowledge present today,
while it is clear that regulation of Oct-2 or Grg/TLE would
logically complete the present model, as would informa-
tion about other genetic feedback loops between the virus
and its host cell. This then defines important tasks for the
future.
Latency escapes and model robustness Figure 5
Latency escapes and model robustness. Figure showing the minimum instantaneous change in EBNA-1 protein number 
necessary to switch from latency I to III and vice versa, as a function of the number of Oct-2+Grg/TLR proteins. For small num-
bers only the latency III state exists, while for large numbers only latency I state exists, compare Figure 3 and Figure 4. Left fig-
ure: red lines are at the reference parameter values, in particular Oct-2 complex binding with affinity KdOFR = 2.5 nM and an 
EBNA-1 dimerization dissociation constant of 1 nM. Blue lines show a five-fold weaker Oct-2 affinity (KdOFR = 12.5 nM). Similar 
behaviour is then displayed at approximately five-fold higher Oct-2 level. Right figure: red solid and dotted lines at reference 
parameter values. Blue solid and dotted lines at a tenfold stronger EBNA-1 dimerization, and green solid and dotted lines at a 
tenfold greater volume. The latency III state is relatively robust towards either of these changes, while the latency I state 
changes more. Black solid and dotted lines show both a tenfold stronger EBNA-1 dimerization and a tenfold greater volume. 
This influences the latency III state more, essentially because EBNA-1 concentration in the latency III state is then comparable 
to the EBNA-1 dimerization dissociation constant.
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Conclusion
We have here shown that fundamental properties of the
EBV infection, with high relevance for the virus as a risk
factor in human cancer, can be modelled and understood
mathematically. The model involves mechanisms which
have, to our knowledge, only been used in models of sim-
pler genetic systems before. However, also for this more
complex system, these mechanisms nicely describe the
dynamics and the properties of the viral genetic control.
A first conclusion is that EBNA-1 and Oct-2+Grg/TLE reg-
ulation of Cp and Qp is enough to establish mutually
exclusive expression patterns, correlating with experimen-
tal data. Secondly, the switch manifests both mono- and
bistable behavior, with the latency III state being mark-
edly more robust. This in turn results in very different
transition time scales between the latency states.
Our results and predictions moreover stress the impor-
tance, of the largely unknown regulation of the human
transcription factor Oct-2 to the life-cycle of EBV.
Methods
Model base and main assumptions
As described in Background, our model is a simplification
of the in vivo viral system, in the sense that it only involves
promoter control by two transcriptional factors, EBNA-1
and Oct-2, with co-factors. The premise is that other regu-
latory factors documented in the literature, are less impor-
tant as concerns the basic properties of the switch.
Regarding DNA binding of transcription factors to DNA,
particularly to the FR region, the model assumes inde-
pendent binding of both EBNA-1 and Oct-2. Moreover,
bound proteins exclude only other bindings at that spe-
cific site, but do not affect neighbouring sites The octamer
sites found in FR suggests a monomer binding of Oct-2,
which we assume in our model, although the possibility
of dimer bindings cannot be ruled out. The system is
modelled with one kinetic equation, describing the
dynamics of EBNA-1, coupled with thermodynamic equi-
librium probabilities for transcription factor binding, to
estimate transcription rates from Cp and Qp. As no regu-
lation of Oct-2 levels by viral factors is known, Oct-2 level
are essentially an external parameter to the model. The
dynamics is modelled deterministically, disregarding
noise in the transcription and translation (see Discus-
sion). Details concerning parameter estimates are dis-
cussed in the following section.
Parameters
It is evident that all modelling results depend on the
parameters used, resulting in a demand for exact parame-
ters, or good estimates based on experimental studies. In
Table 1 we list the parameters used in this study. These
include the EBNA-1 dimerization constant, DNA binding
dissociation constants, steady state level of EBNA-1 in
latency III together with EBNA-1 half-life time, cell divi-
sion time and the volume of the system.
Of central importance in this model are the binding affin-
ities for our transcription factors to the FR region and Qp
sites. The dissociation constant for EBNA-1 binding to FR
and the relative dissociation constant for the Qp sites was
determined by Ambinder et al., 1990. Their experimental
results give a dissociation constant, KdEFR, for EBNA-1
from FR that is 15 pM and a KdQ from the Qp binding sites
that is 14 times higher [39]. Regarding EBNA-1 dimeriza-
tion, EBNA-1 is known to be in dimer form in solution
and bind DNA as a dimer [40], but the exact dimerization
constant has however not been experimentally deter-
mined. We have used a KdE value of 1 nM as reference
Dynamics of EBNA-1 and Oct-2 Figure 6
Dynamics of EBNA-1 and Oct-2. This plot illustrates 
how changes in Oct-2 levels affect the EBNA-1 levels. At 
time zero the system is stable in latency I, with an EBNA-1 
level of 850 molecules, and an Oct-2 level of 15000 mole-
cules. Transition to latency III is induced by lowering the 
Oct-2 level to 10000, activating the C promoter. Reaching 
the stable latency III level of EBNA-1 proteins thereafter take 
a few days. Induced switching back to resting latency I state 
demands a distinct increase in Oct-2, minimum a 10 fold 
change (green solid line). The greater increase in Oct-2 mol-
ecules the faster the cell is switched back to a stable latency I 
level of EBNA-1. The green solid and dashed line illustrate 
two different scenarios of elevated Oct-2 levels, where the 
red solid and dashed line are the corresponding resulting 
EBNA-1 levels.
0 5 10 15 20
0
1
2
3
4
5
6
7
8
9
10
11
x 10
4
time [days]
E
B
N
A
−
1
 
a
n
d
 
O
c
t
−
2
 
l
e
v
e
l
s
 
[
m
o
l
e
c
u
l
e
s
]
 
 
EBNA−1
EBNA−1
Oct−2
Oct−2BMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
Page 11 of 13
(page number not for citation purposes)
value, but varied this parameter to examine its impact on
the system.
Oct-2 belongs to the POU family of proteins, which share
two distinct DNA-binding subdomains; a POU-specific
domain and a POU homeodomain. The ATGC half of the
octamer sites is recognized by the POU-specific domain,
and the homeodomain binds to the AAAT half [41]. Oct
proteins therefore bind octamer sites as monomers,
although they are able to form dimers and bind to similar
palindromic sites known as MORE and PORE. In the FR
region, the binding sites present are octamer-like; hence
Oct-2 is assumed to bind as a monomer. The Oct-2 disso-
ciation constant for the consensus octamer site,
ATGCAAAT is known to be 2.5 nM [41]. The octamer sites
in FR are however not perfect, and most sites noticeably
have an A6G variant in the last half of the sequence, and
at least two base exchanges in the first half. From pub-
lished mutational analyses of Oct-2 and Oct-1 octamer
sites we can however deduce that the homeodomain gen-
erally has a higher binding affinity that the POU-specific
domain, and that an A6G mutation does not dramatically
affect the affinity [41,42]. The dissociation constant of the
Oct-2+Grg/TLE complex to sites within FR, KdOFR, is there-
fore here assumed to be 2.5 M but the effects of a higher
dissociation constant was also tested.
The transcription rates for Cp and Qp and the translation
rate for EBNA-1 transcripts are not experimentally known.
As our model does not describe the transcription and
translation steps individually but uses a total production
rate, we incorporate both rates into one. Estimation of this
production rate comes from experimentally determined
steady state levels of EBNA-1 in latency III cell lines.
Sternås et al. measured these EBNA-1 levels to range from
25,000 to 44,000 with an approximate mean value
around 34,000 [43]. This roughly corresponds to a pro-
duction of 34,000 new EBNA-1 proteins every cell cycle,
when production is balanced by dilution and degradation
of EBNA-1.
The exact half-life of EBNA-1, τ1/2, is not known, but
experiments indicate that it is at least 48 hours, probably
due to the Gly-Ala repeat domain which inhibits proteas-
omal degradation [44,45]. In our study we have hence
chosen a half-life of 48 hours, and the cell division time is
set to be 24 hours [46]. The model assumes an homoge-
neous distribution of molecules in the system and does
not include spatial movements between different cellular
compartments. EBNA-1 is mostly located in the nucleus,
due to its functions in transcriptional and translational
control [47]. Our system volume therefore corresponds to
the nuclear volume of B-cells, a spherical volume with a
diameter of 7 µm [48].
Physico-chemical model
The EBNA-1 dynamics is studied with a non-linear differ-
ential equation, (Eq. 1) describing production of EBNA-1
(E) from both promoters, Cp and Qp, protein degrada-
tion and also dilution, in the case of proliferating cells.
The production from Cp is computed as the probability of
gene transcription Pc, times the rate of protein production
rc (including transcription and translation), and likewise
for Qp. Dilution is computed with a continuous dilution
rate rdil, for cells that are in proliferating state. Degradation
is computed with the continuous degradation rate rdeg.
The switch from resting to proliferating state is modelled
instantaneously, meaning that the dilution rate is turned
on as soon as Cp activity is higher than Qp activity,
although in the real cell there is probably some delay. The
total number of EBNA-1 molecules, Etot, in the system
includes the free monomers, E, the dimers, Ed, and the
dimers bound specifically to DNA, EDNA, (Eq. 2). EDNA is
computed as the mean value of bound EBNA-1 dimers
and has to be calculated iteratively from the binding prob-
abilities at each time step of a dynamic simulation, since
it is dependent on the dimer concentration. The kinetic
equation for EBNA-1 then reads;
where Etot is defined as;
Etot = 2Ed + E + 2EDNA (2)
Transcriptional probability
The promoter transcription probability is computed from
the probability of having a combination of transcription
factors bound at the operator that allows for transcrip-
tional activation. Full activation of Cp requires at least
eight bound EBNA-1 dimers out of the 20 available sites
at FR [14,15]. The independent binding of EBNA-1 and
Oct-2+Grg/TLE means treating the 40 separate sites as 20,
where each site can be occupied by either EBNA-1 or Oct-
2+Grg/TLE. The transcription activity of Qp is dependent
only on the EBNA-1 level, where transcription is blocked
when one or two EBNA-1 dimers are bound.
In thermodynamic models, the probability of a certain
combination of bound complexes is evaluated from the
Boltzmann weight, Z, describing that state normalized
with the sum of the weights for all possible states, Ztot. For
FR, the statistical weight of having n EBNA-1 and k Oct-
2+Grg/TLE bound to the N number of sites, Znk, depend
on the binding free energies of EBNA-1 and Oct-2+Grg/
TLE, EeFR and Eo, to their specific DNA sites, the concentra-
tions of EBNA-1 and Oct-2+Grg/TLE, [E] and [O], and the
number of different possible binding combinations that
state can occur (Eq. 3). In the case of statistical weights for
dE
dt
Errr P r P tot
tot deg dil c c q q =− ∗ + + + () (1)BMC Systems Biology 2007, 1:40 http://www.biomedcentral.com/1752-0509/1/40
Page 12 of 13
(page number not for citation purposes)
Q promoter activity, these are computed in the same man-
ner, only dependent on EBNA-1 free energies, EeQ, and
concentration [E] (Eq. 4). The number of binding sites, N,
is 20 for FR and 2 for Qp.
Experiments
Western Blot
Protein concentration of nuclear extracts of latency I and
III cells was determined by Bio-Rad Dc protein assay (Bio-
Rad, Hercules, CA). The same amount of nuclear extract
was loaded on every lane. Proteins were fractionated by
9% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to nitrocellulose
membranes. After blocking for 1 h at room temperature
with 5% milk, made up in PBS- 0.1% Tween 20 (PBST),
the membranes were probed overnight at 4°C with the
following antibodies at indicated dilutions. Anti Beta-
Actin (Sigma) was used as second protein control; Oct-2
(Santa Cruz Biotechnologies, Santa Cruz, Calif.) were
used at 1:2000 and anti- EBNA1 used at 1:1000 (OTX-1, a
kind gift from Jaap Middeldorp, Amsterdam Free univer-
sity). The second antibody used was horseradish peroxi-
dase-conjugated (HRP) and bound immunocomplexes
were detected by enhanced chemiluminscence (ECL;
Amersham Life Science, Little Chalfont, Buckingham-
shire, United Kingdom).
Chromatin immunoprecipitation assay (ChIP)
2 * 106 EBV latency type I Rael cell or latency III CBMI-Ral-
Sto cell were collected. Proteins were cross-linked to DNA
by adding formaldehyde to 1% of culture medium. Cell
pellets were collected after 10 min incubation at 37°C.
The cell pellets were resuspended in SDS lysis buffer, DNA
sheared to 500–1000 bp by sonicating the lysate. The son-
icated samples were diluted 10 fold and 2 ug of immuno-
precipitating antibody was added respectively: OTiX,
mouse monoclonal antibody anti EBNA1, (kindly pro-
vided by Dr Jaap Middeldorp, Amsterdam), anti-OCT2
(C-20); rabbit polyclonal antibody, Santa cruz Biotech-
nology, California; Goat polyclonal antibody Santa cruz
Biotechnology, California, and rotated at 4C overnight.
100 ul of salmon sperm DNA/protein A agarose -50%
slurry was added to collect antibody/protein/DNA com-
plex. After washes and elution, the complexes were reverse
crosslinked by adding sodium chloride to final concentra-
tion 0.2 M and kept at 65C for at least 6 hrs. Proteins were
digested by proteinase K then DNA was purified by phe-
nol/Chlorofome/ethanol precipitation. PCR primers were
FRjz1S: TCCCTCTGGGAGAAGGGTAT and FRjz1A:TTT-
TCGCTGCTTGTCCTTTT for family of repeats (FR). For
control experiments to exclude non-specific binding of
antibodies to DNA, the immunopreciptated DNA was
analyzed with primers to beta-actin: AC-S:
ATCATGTTTGAGACCTTCAA and AC-A: CATCTCTT-
GCTCGAAGTCCA. DNA from latency III cell lysate (Mutu
III) was immunopreciptated with 4 ug of anti-Oct2 or 4 ug
of anti-EBNA1 and amplified by PCR with primers to
beta-actin. Water and reaction without antibody was used
as negative controls, while cell lysate DNA prior to immu-
nopreciptation was used as positive control.
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